Axsome Therapeutics reported second quarter 2026 financial results with total net product revenue of $218.4 million, a 46% year-over-year increase driven by strong demand for its CNS portfolio. AUVELITY sales reached $180.3 million (51% growth) following its June 2026 launch for Alzheimer’s disease agitation, while SUNOSI revenue grew 20% to $35.8 million and SYMBRAVO sales increased 461% to $2.3 million. The company reported a net loss of $51.3 million, or $(0.99) per share, compared to a $48.0 million loss in the prior year period. Axsome also announced that its NDA for AXS-12 for cataplexy was accepted by the FDA with a PDUFA date of May 1, 2027, and initiated Phase 3 trials for solriamfetol in pediatric ADHD. The company operates as a biopharmaceutical firm focused on developing treatments for central nervous system disorders.

On July 15, 2026, the U.S. Food and Drug Administration accepted for filing the New Drug Application for AXS-12 (reboxetine) to treat cataplexy in patients with narcolepsy. Axsome Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies for neurological and psychiatric disorders.

On June 5, 2026, Axsome Therapeutics adopted an Executive Severance and Change in Control Plan. The plan establishes three tiers of participants: Tier 1 (CEO), Tier 2 (Section 16 executive officers), and Tier 3 (Vice Presidents and above). Involuntary termination outside a change in control provides cash severance of 18, 12, or 6 months of base salary based on tier. Termination during a change in control period provides enhanced benefits, including increased cash severance (24, 18, or 9 months), target annual incentive payments, and 100% accelerated vesting of time-based equity awards. The company is a biopharmaceutical company that develops therapies for central nervous system disorders.

At the 2026 Annual Meeting of Stockholders held on June 5, 2026, Axsome Therapeutics, Inc. stockholders elected Mark Saad and Susan Mahony, Ph.D., MBA to serve as Class II directors. The meeting also resulted in the ratification of Deloitte & Touche LLP as the company's independent registered public accounting firm for the 2026 fiscal year and the approval of executive compensation on a non-binding advisory basis. Axsome Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing therapies for central nervous system disorders.